Sugi Predict

Sugi Predict / Compounds / SCHEMBL924173

SCHEMBL924173

SCHEMBL924173

O=C(OCc1ccccc1)C1CNCCO1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.46
▸ SLC6A2 P23975 2/20 0.44
▸ SSTR4 P31391 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ FABP7 O15540 1/20 0.43
▸ FABP5 Q01469 1/20 0.43
▸ REN P00797 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL999381 0.99 TSHR (0.45) HTR2CSLC6A2SSTR4TSHRFABP7
SCHEMBL19830987 0.82 TSHR (0.49) SLC6A2TSHRFABP7FABP5KMT2A
SCHEMBL16648788 0.79 ALDH1A1 (0.52) SLC6A2TSHRFABP7FABP5KMT2A
SCHEMBL19749101 0.79 ALDH1A1 (0.52) SLC6A2TSHRFABP7FABP5KMT2A
SCHEMBL29433900 0.79 ALDH1A1 (0.52) SLC6A2TSHRFABP7FABP5KMT2A
SCHEMBL23286062 0.78 GLA (0.50) HTR2CSLC6A2KMT2AMEN1NPSR1
SCHEMBL17028386 0.78 SSTR4 (0.43) SLC6A2SSTR4RENALDH1A1SLC6A3
SCHEMBL7261536 0.78 ALDH1A1 (0.56) TSHRFABP7FABP5NPSR1ALDH1A1
SCHEMBL8101751 0.78 SLC6A2 (0.47) SLC6A2SSTR4REN
Hydrochloric Acid SCHEMBL29854262 0.77 GLA (0.49) HTR2CSLC6A2KMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106967066-B Novel ss-lactam enzyme inhibitor and preparation method thereof 明治制果药业株式会社 2019-07-30 — — CN disclosed
CN-105859609-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2019-04-09 — — CN disclosed
CN-106967066-A New beta lactamase restrainer and preparation method thereof 明治制果药业株式会社 2017-07-21 — — CN disclosed
CN-104334559-B Beta-lactamase inhibitor and preparation method thereof 明治制果药业株式会社 2017-03-22 — — CN disclosed
CN-105859609-A Beta-lactamase inhibitor and process for preparing the same 明治制果药业株式会社 2016-08-17 — — CN disclosed
CN-104334559-A Novel beta-lactamase inhibitor and process for preparing the same MEIJI SEIKA PHARMA CO LTD 2015-02-04 — — CN disclosed
EP-2280705-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-10-08 — — EP disclosed
EP-2280705-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-10-08 — — EP disclosed
US-RE45183-E1 Heteroaryl-ureas and their use as glucokinase activators NOVO NORDISK A/S (DK) 2014-10-07 — — US disclosed
US-8536169-B2 Compounds GLAXO GROUP LIMITED (GB) 2013-09-17 — — US disclosed
WO-2009147189-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-10 — — WO disclosed
US-7598391-B2 Heteroaryl-ureas and their use as glucokinase activators NOVO NORDISK A/S (DK) 2009-10-06 — — US disclosed
US-20090216013-A1 e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes NOVO NORDISK A/S (DK) 2009-08-27 — — US disclosed
EP-1954693-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2008-08-13 — — EP disclosed
US-20070185103-A1 Beta-secretase modulators and methods of use AMGEN INC. 2007-08-09 — — US disclosed
WO-2007062007-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 — — WO disclosed
US-20070054897-A1 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes NOVO NORDISK A/S (DK) 2007-03-08 — — US disclosed
CN-1910166-A Heteroaryl ureas and their use as glucokinase activators NOVO NORDISK AS (DK) 2007-02-07 — — CN disclosed
EP-1723128-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2006-11-22 — — EP disclosed
WO-2005066145-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185103-A1 Beta-secretase modulators and methods of use BACE1, BACE2, APP HTR2C 3212/4885SLC6A2 4696/4885SSTR4 3228/4885
US-20090216013-A1 e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes GCK, GCKR, HK1 HTR2C 3350/4885SLC6A2 3824/4885SSTR4 2096/4885
US-20070054897-A1 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes GCK, GCKR, HK1 HTR2C 3359/4885SLC6A2 3811/4885SSTR4 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.